Bengaluru-based home healthcare company Portea has reported a steady improvement in its financial performance for the financial year ended March 2025. As per its latest regulatory filings, the company recorded ₹160 crore in operating revenue in FY25, marking a healthy growth of around 15% compared to ₹139 crore in the previous fiscal year.
More importantly, Portea managed to significantly reduce its losses during the year. The company’s net loss narrowed to ₹19 crore in FY25, compared to ₹37 crore in FY24, reflecting a sharp 49% decline in losses. This improvement highlights stronger operational efficiency and better cost controls across the organisation.
Core Healthcare Services Drive Revenue Growth
Portea’s business continues to be anchored in its wide range of home healthcare services. These include home nursing, physiotherapy, diagnostics, doctor consultations, medical equipment rentals and trained attendants. During FY25, services contributed nearly 59% of total operating revenue, generating around ₹95 crore, up by 16% year-on-year.
According to Entrackr, the company also saw stable momentum in its product segment. Sales of medical devices and equipment such as oxygen concentrators, nebulisers and BiPAP machines rose 14% to about ₹56 crore, further supporting overall revenue growth. The balanced contribution from services and product sales helped Portea strengthen its topline in a challenging healthcare environment.
Read More: Cars24 Cuts Cash Burn by 36% in H1 FY26 While Posting ₹651 Crore Adjusted Revenue
Tighter Cost Controls Improve Unit Economics
While Portea’s total expenses remained largely flat at around ₹179 crore, the company made meaningful progress in optimising its spending. Employee benefit expenses declined by 4.5% to ₹52.5 crore, indicating better manpower planning and productivity improvements.
However, some cost heads witnessed an increase. Consultancy charges went up by 7% to approximately ₹44 crore, while material costs rose by 21%. Advertising and promotional spending also increased by 25%, reflecting higher investment in brand visibility and customer acquisition. Other operational expenses, including legal, professional and finance costs, together crossed ₹30 crore.
Despite these rises, Portea improved its cost efficiency. In FY25, the company spent ₹1.12 to earn every ₹1 of operating revenue, compared to ₹1.29 in FY24, signalling a meaningful improvement in unit economics.
Profitability Metrics Still Under Pressure
Although losses narrowed, Portea’s profitability ratios remain in the red. The company reported a negative ROCE of around 40% and an EBITDA margin of -6.9% in FY25. These figures underline that while the business is moving in the right direction, achieving sustained profitability remains a work in progress.
As of March 2025, Portea reported ₹1 crore in cash and bank balances and nearly ₹68 crore in current assets, indicating a modest but stable liquidity position.
Funding History and IPO Status
Portea has raised substantial capital over the years to support expansion and technology development. The company has secured close to $123 million in funding, with backing from prominent investors such as Accel and Ventureast.
In 2023, Portea received regulatory approval to launch a ₹1,000 crore initial public offering. However, despite receiving clearance, the company has not yet announced a concrete timeline for its IPO, suggesting a cautious approach amid market conditions.
Outlook for the Home Healthcare Sector
Portea’s FY25 performance reflects improving fundamentals in India’s home healthcare space, which continues to benefit from rising healthcare awareness, an ageing population and increasing demand for at-home medical services. While competition in the sector remains intense, Portea’s focus on cost discipline and service-led growth has helped it move closer to financial stability.
Going ahead, the company’s ability to scale profitably while maintaining service quality will be critical as it navigates the next phase of growth in India’s evolving healthcare ecosystem.